Boston Scientific Corporation $BSX Shares Purchased by Motco

Motco lifted its position in Boston Scientific Corporation (NYSE:BSX) by 65.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 534 shares of the medical equipment provider’s stock after purchasing an additional 212 shares during the period. Motco’s holdings in Boston Scientific were worth $56,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. 1248 Management LLC acquired a new position in shares of Boston Scientific in the 1st quarter valued at $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC lifted its stake in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. Princeton Global Asset Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific in the 2nd quarter worth $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Boston Scientific stock opened at $100.20 on Thursday. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The firm has a market capitalization of $148.47 billion, a price-to-earnings ratio of 53.58, a PEG ratio of 2.03 and a beta of 0.61. The company has a fifty day simple moving average of $100.96 and a 200-day simple moving average of $102.26. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 earnings per share. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on BSX shares. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $123.77.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 9,990 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $101.13, for a total transaction of $1,010,288.70. Following the transaction, the director directly owned 27,035 shares in the company, valued at approximately $2,734,049.55. The trade was a 26.98% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 180,204 shares of company stock valued at $18,544,846. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.